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LAPTM4B is a newly cloned gene that shows an active role in many solid tumors progression in substantial researches,
mainly through the autophage function. Accumulated studies have been conducted to determine the association of
LAPTM4B polymorphism with cancer risk. While the results are inconsistent, we conducted the meta-analysis to determine
the strength of the relationship. Results showed that allele*2 carriers exhibited a significantly increased risk of
cancer development with comparison to allele*1 homozygote (for *1/2, OR = 1.55, 95% CI 1.367-1.758; for *2/2,
OR = 2.093, 95%CI 1.666-2.629; for *1/2 + *2/2, OR = 1.806, 95%CI 1.527-2.137). We also observed a significant association
between *2/2 homozygote and cancer risk with comparison to allele*1 containing genotypes (OR = 1.714, 95%CI
1.408-2.088). Allele*2 is a risk factor for cancer risk (OR = 1.487, 95%CI 1.339-1.651). Stratified analysis by tumor
type exhibits the significant association of this genetic variants with various cancers. In conclusion, LAPTM4B
polymorphism is associated with cancer risk and allele*2 is a risk factor.
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Lysosomes are organelles that contain hydrolytic en-
zymes such as proteases, nucleases and lipases. The sta-
bility of lysosomal membrane and the normality of
lysosomal function are essential in cellular biology.
Lysosomal-membrane permeabilization (LMP) can pose
a threat to cellular homeostasis through release of lyso-
somal contents, such as lysosomal cathepsins B or D,
and is a recognized trigger of cell death (Johansson et al.
2010). Autophagy is a conserved lysosome-mediated
intracellular trafficking pathway that degrades and recy-
cles intracellular components, thereby promoting cell
survival as well as the adaption to a variety of cell
stresses as cancers develop and disseminate (Burman
and Ktistakis 2010; Jin and White 2007; Degenhardt
et al. 2006; Kenific et al. 2010). Noticeably, too much au-
tophagy may conversely result in autophagic cell death* Correspondence: bszhou@mail.cmu.edu.cn
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in any medium, provided the original work is p(Scarlatti et al. 2009; Eisenberg-Lerner et al. 2009). Lyso-
somal retention of drugs is responsible for drug resistance
and lysosomal concentration of anthracyclines is consid-
ered to increase drug efflux and decrease drug nuclear
localization, thereby preventing effective chemotherapy-
induced DNA damage (Larsen et al. 2000).
Lysosome-associated protein transmembrane 4 beta
(LAPTM4B) is a recently discovered gene mapped to
chromosome 8q22.1 with 7 exons and 6 introns span-
ning at least 50 kb (Shao et al. 2003). LAPTM4B pro-
tein has a lysosome localization motif and co-localizes
with markers of late endosomes and lysosomes (Shao
et al. 2003; Li et al. 2011; Vergarajauregui et al. 2010).
LAPTM4B is required for the later stages of autophagy
maturation in which autophagosomes are fused with
lysosomes to form autolysosomes, the place where
cytosol and damaged organelles are discomposed into
micro molecules and new macro molecules and ATPs
are synthetized, thereby maintaining the cellular
homeostasis (Li et al. 2011). The transcriptional prod-
ucts of the gene have been observed over-expressed in
many solid tumors (Kasper et al. 2005) and differentpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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et al. 2003), exerting various functions. Up-expression of
LAPTM4B inhibits lysosome-mediated death pathways,
promotes autophagy and leads to stress tolerance,
thereby enhancing tumor cell growth, survival and re-
sistance to apoptosis. Down regulation of LAPTM4B
triggers lysosome membrane permeabilization (LMP),
weekening the capability of lysosomes to retain the
drug and provoking lysosomal-mediated programmed
cell death (Li et al. 2011). Evidences from Maeda, et al.
study suggest that the transcriptional product of this
gene results in an active role in the progression of cell
proliferation other than results from tumor genesis
(Maeda et al. 2005) and LAPTM4B proteins play an influ-
ential role in occurrence, development, progression and
prognosis of cancer cells (Zhou et al. 2008; Yang et al.
2010b; Li et al. 2010b; He et al. 2003; Yang et al. 2010a).
Allelic loss of essential autophage gene can lead to tumor
formation in beclin1+/− mutant mice (Qu et al. 2003; Yue
et al. 2003; Liang et al. 1999), indicating the role for poly-
morphisms of autophage-associated gene in tumor sup-
pression. LAPTM4B has two alleles, LAPTM4B allele*1
and LAPTM4B allele*2, encoding proteins with 35kD and
40kD respectively (Liu et al. 2003). Allele*1 contains one
copy of a 19-bp sequences at the 5’UTR of the first exon,
while the segment is duplicated and tandemly arranged in
allele*2. This polymorphism may alter its opening reading
frame (ORF) and perform as a cis-acting elememt and par-
ticipate in genetic translation or tissue specific expression
with some transcriptional factors or nucleoproteins (Zhou
et al. 2008; Yang et al. 2010b). The relationship between the
genetic polymorphisms and cancer susceptibility has been
studied while the conclusions are not accordant (Deng
et al. 2005; Li et al. 2006; Liu et al. 2007; Sun et al. 2007;
Cheng et al. 2008; Sun et al. 2008; Wang and Zhang 2010;Figure 1 The flowchart of the selection process.Qi 2010; Meng et al. 2011; Fan et al. 2012; Li et al. 2012;
Yang et al. 2012; Wang et al. 2012; Zhai et al. 2012; Xu
et al. 2012; Meng et al. 2013; Wang et al. 2013; Tang et al.
2014). To evaluate the association of LAPTM4B polymor-
phisms and the risk of cancer development, we conducted
a meta-analysis of 18 enrolled case–control studies includ-
ing gynecological tumors (Meng et al. 2011; Meng et al.
2013; Xu et al. 2012), digestive system cancers (Wang and
Zhang 2010; Zhai et al. 2012; Yang et al. 2012; Qi 2010;
Cheng et al. 2008; Liu et al. 2007; Wang et al. 2012; Sun
et al. 2008), lung cancer (Li et al. 2006; Deng et al. 2005;
Tang et al. 2014), breast cancer (Fan et al. 2012; Li et al.
2012), nasopharyngeal carcinoma (Wang et al. 2013), and
lymphoma (Sun et al. 2007).
Results
Characteristics of the studies
The flowchart of the selection of eligible studies is shown
as Figure 1. The major information of the publications is
listed in Table 1.Totally, 18 eligible case–control studies
published from 2005 to 2014 were recruited in this meta-
analysis. The countries of origin and ethnic group of these
studies are not shown in the table for the study populations
are all Chinese. All of the enrolled studies comply with
Hardy-Weinberg Law.
Main results
Table 2 shows the main results of pooled OR and 95%
CI for LAPTM4B polymorphism and cancer risk. Gener-
ally speaking, allele*2 carriers showed a significant asso-
ciation with cancer risk. When adjusted by age, gender,
et al., the association between LAPTM4B polymorphism
and cancer susceptibility is also observed (Additional file
1: Table S1). The forest plots of the pooled OR and 95%
CI for the five genetic models are shown as Figure 2.
Table 1 Characteristics of studies eligible in the meta-analysis
Author Year Type of tumor Numbers Genotype(case/control) MAF (%) P(HWE)
case control *1/1 *1/2 *2/2
Deng et al. (2005) 2005 Lung cancer 166 134 54/67 91/59 21/8 75(28.0) 0.2850
Li et al. (2006) 2006 Lung cancer 131 104 70/57 56/36 5/11 58(27.9) 0.1554
Liu et al. (2007) 2007 Gastric cancer 214 350 88/199 107/133 19/18 169(24.1) 0.4835
Sun et al. (2007) 2007 lymphoma 166 350 72/199 71/133 23/18 169(24.1) 0.4835
Cheng et al. (2008) 2008 Colon cancer 253 350 113/199 112/133 28/18 169(24.1) 0.4835
Rectal cancer 237 350 126/199 101/133 10/18 169(24.1) 0.4835
esophageal cancer 211 350 123/199 80/133 8/18 169(24.1) 0.4835
Sun et al. (2008) 2008 hepatocellular 190 175 72/99 110/67 8/9 85(24.3) 0.587
Wang and Zhang (2010) 2010 Pancreatic cancer 58 156 24/74 26/67 8/15 97(31.1) 0.9766
Qi (2010) 2010 liver 86 77 27/36 51/34 8/7 48(31.2) 0.7985
Meng et al. (2011) 2011 Cervical cancer 317 416 127/225 153/163 37/28 219(26.3) 0.8352
Fan et al. (2012) 2012 breast 732 649 326/346 342/262 64/41 344(26.5) 0.3556
Li et al. (2012) 2012 breast 208 211 90/129 100/76 18/6 88(20.9) 0.1853
Yang et al. (2012) 2012 Gallbladder cancer 91 155 34/88 45/57 12/10 77(24.8) 0.8508
Wang et al. (2012) 2012 liver 303 515 107/272 156/205 40/38 281(27.3) 0.9415
Zhai et al. (2012) 2012 hepatocellular 102 135 37/ 52/ 13/ (24.07) -
Xu et al. (2012) 2012 ovarian 282 365 122/231 115/108 45/26 160(21.9) 0.64
Meng et al. (2013) 2013 Endometrial cancer 283 378 93/200 135/140 55/38 216(28.6) 0.0718
Wang et al. (2013) 2013 nasopharyngeal cancer 134 327 74/163 48/145 12/19 183(28.0) 0.0700
Tang et al. (2014) 2014 NSCLC 392 437 158/226 171/176 63/35 246(28.1) 0.9284
*MAF, minor allele frequency, in this study, minor allele refers to allele*2, P (HWE), P value for test of Hardy-Weinberg equilibrium.
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between LAPTM4B expression and cancer prognosis was
conducted. Results are shown in Additional file 2: Table S3.
Overexpression of LATPM4B may be a risk predictor for
poor survival. The articles eligible for this meta-analysis are
listed in Additional file 3: Table S2.
Subgroup analysis results
The results of stratified analysis by tumor type are listed in
Table 3. Stratified analysis results suggested that allele*2
may increase the risk of multiple cancers. Overexpression
of LAPTM4B is also associated with poor prognosis in
multiple cancers (Additional file 4: Table S4).Table 2 The pooled ORs and 95%CIs for the association betw
Models No. of studies No. of population
(case/control)
*2 vs *1 18 4556/4584
*1/2 vs *1/1 17 4454/4449
*2/2 vs *1/1 17 4454/4449
*1/2 + *2/2 vs *1/1 17 4454/4449
*2/2 vs *1/2 + *1/1 17 4454/4449
*P(H): P-value for test of heterogeneity, P(P): P value for test of publication bias.Sensitivity analysis
A sensitivity analysis was performed by omitting every
study in turn to find potential outliers to check the in-
clusion criteria. Pooled estimates for all genetic models
were insensitive to the removal of individual study, and
the corresponding pooled ORs were not substantially al-
tered, indicating that our results were stable and reliable
(data not shown).Publication bias
Begger’s plot funnel and Egger’s test were performed to
examine the underlying publication bias. The symmetricaleen LAPTM4B polymorphism and cancer susceptibility
OR 95%CI P P(H) P(P)
1.487 1.339-1.651 <0.001 <0.001 0.667
1.550 1.367-1.758 <0.001 0.004 0.759
2.093 1.666-2.629 <0.001 0.005 0.099
1.806 1.527-2.137 <0.001 <0.001 0.564
1.714 1.408-2.088 <0.001 0.034 0.064
Figure 2 The pooled Ors and 95%CIs for the relationship between LAPTM4B polymorphism and cancer susceptibility. The forest plot for
relationship between LAPTM4B polymorphism and cancer susceptibility for *2 vs *1 (a), *1/2 vs *1/1 (b), *2/2 vs *1/1 (c), *1/2 + *2/2 vs *1/1
(d), *2/2 vs *1/2 + *1/1 (e).
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publication bias in this meta-analysis (Figure 3).
Discussion
Due to insufficient angiogenesis, tumors frequently ex-
perience elevated metabolic stress from nutrient and
oxygen deprivation (Jin and White 2007; Folkman 2003).
Survival mechanisms such as autophagy may be more reli-
able for cancer cells to maintain growth or to disseminate
(White and DiPaola 2009). Many studies have shown the
roles of LAPTM4B in limiting cell death and promoting
autophagy (Li et al. 2011; He et al. 2003; Yang et al. 2010a).
To date, the exact molecular mechanism that might be
involved in progressive phenotypes caused by LAPTM4B
protein remains unclear. Nonetheless, accumulated de-
tections in other studies may demonstrate the functional
mechanism to some extent.
Both the C- and N-terminal of LAPTM4B protein
contain a proline-rich domain PXXP, forming a specific
src-homology 2 (SH2) binding domain at C-terminal
and specific src-homology 3(SH3) binding domain at
N-terminal. The functional domain in C-terminal has a
lysosome localization motif, sharing the same domain
with the markers of endosomes and lysosomes (Liu et al.
2004; Hunziker and Geuze 1996; Honing et al. 1998;
Dell’Angelica et al. 2000; Hogue et al. 2002). And the
N-terminal offers sites for SH3-containing proteins
such as phosphoinositide 3-kinase (PI3K), protein
phosphatase 2A and protein kinase C (PKC) (Shao
et al. 2003; Liu et al. 2004). We hypothesized that C-
terminal is responsible for positioning and N-terminal
is responsible for the function. LAPTM4B plays a sig-
nificant role in cell cycle progression throughregulation of c-Myc, cyclinD1/E and p27 (He et al.
2003; Yang et al. 2010a; Liu et al. 2009). Up-expression
of LAPTM4B proteins promoted the phosphorylation
of AKT, the pivotal signaling pathway in cell survival
and proliferation (Cantley 2002; Yang et al. 2010a;
Medema et al. 2000). Moreover, LAPTM4B can de-
crease the expression of p16, increase the expression of
c-Fos, c-Jun (Yang et al. 2010a; Liu et al. 2009; Zhou
et al. 2010b), and phosphorylate Rb (Retinoblastoma
protein) (Yang et al. 2010a). Another study (Li et al.
2010a) suggested that LAPTM4B may promote drug ef-
flux and multidrug resistance through PI3K/AKT path-
way and thus results in poor prognosis.
A high level of expression of LAPTM4B protein has
been observed in cells with tendency of migration and
metastasis, while the knockdown of the genetic expres-
sion reverses the propensity of growth, proliferation
and malignancy (Li et al. 2010b; He et al. 2003; Liu et al.
2009). In Zhou, et al. (Zhou et al. 2010a) study, we observed
that the over-expression of LAPTM4B enhanced the ex-
pression of MMP-2, MMP-9 and uPA (Milde-Langosch
2005). Among them, MMP-9 and uPA are targets of activa-
tor protein (AP-1) (Milde-Langosch 2005). Given the fact
that no binding site of AP-1 was found in promoter region
of MMP-2 gene (Yan and Boyd 2007) and that uPA can ac-
tivate MMP-2 (Mazzieri et al. 1997), we inferred that
LAPTM4B might activate MMP-2 by up-regulating expres-
sion of uPA.
The allele LAPTM4B*1differs from allele LAPTM4B*2
in that it contains a particular single 19-bp sequence,
whereas LAPTM4B *2 contains two copies of these se-
quences in the 5’UTR of exon 1. This results in the
change in the N terminal of the proteins. Li (Li et al.
Table 3 Stratified analysis for the association between LAPTM4B polymorphism and cancer risk by tumor type
Type of tumor Num *2 vs *1 *1/2 vs *1/1 *2/2 vs *1/1 *1/2 + *2/2 vs *1/1 *2/2 vs *1/2 + *1/1
OR(95%CI) P(H) OR(95%CI) P(H) OR(95%CI) P(H) OR(95%CI) P(H) OR(95%CI) P(H)
Digestive system 8 1.444(1.313-1.588)** 0.011 1.557(1.365-1.777)** 0.034 1.873(1.460-2.402)** 0.082 1.594(1.404-1.809)** 0.009 1.499(1.179-1.906)** 0.204
Gastrointestinal 2 1.334(1.176-1.513)** 0.003 1.332(1.119-1.584)** 0.084 1.603(1.125-2.285)* 0.024 1.359(1.149-1.607)** 0.020 1.400(0.990-1.981) 0.069
Gland 6 1.603(1.387-1.853)** 0.687 1.929(1.573-2.364)** 0.615 2.186(1.539-3.104)** 0.524 1.976(1.625-2.403)** 0.677 1.597(1.144-2.228)* 0.462
Gynecological tumor 3 1.810(1.583-2.069)** 0.253 1.891(1.563-2.287)** 0.584 2.900(2.156-3.901)** 0.638 2.073(1.733-2.480)** 0.400 2.144(1.619-2.839)** 0.716
Breast cancer 2 1.413(1.222-1.635)** 0.058 1.488(1.227-1.806)** 0.187 1.959(1.338-2.868)** 0.075 1.549(1.286-1.865)** 0.101 1.640(1.132-2.376)* 0.116
Lung cancer 3 1.454(1.236-1.710)** 0.026 1.467(1.169-1.842)** 0.458 2.073(1.431-3.002)** 0.004 1.563(1.260-1.939)** 0.164 1.748(1.226-2.492)* 0.006
Others 2 1.309(1.060-1.615)* 0.007 1.063(0.797-1.416) 0.017 2.337(1.420-3.847)** 0.075 2.860(2.184-3.745)** <0.001 2.278(1.403-3.698)** 0.220
*P < 0.05, **P ≤ 0.001, Num: the number of studies, P (H): the P value for test of heterogeneity among studies, Digestive system; include references (Liu et al. 2007; Cheng et al. 2008; Sun et al. 2008; Wang and Zhang
2010; Qi 2010; Yang et al. 2012; Wang et al. 2012; Zhai et al. 2012), Gastrointestinal: include references (Liu et al. 2007; Cheng et al. 2008), Gland: include references (Sun et al. 2008; Wang and Zhang 2010; Qi 2010;
Yang et al. 2012; Wang et al. 2012; Zhai et al. 2012), Gynecological tumor: include references (Meng et al. 2011; Xu et al. 2012; Meng et al. 2013), Breast cancer: include references (Fan et al. 2012; Li et al. 2012), Lung









Figure 3 The funnel plot for the test of publication bias. The funnel plot for *2 vs *1 (a), *1/2 vs *1/1 (b), *2/2 vs *1/1 (c), *1/2 + *2/2 vs *1/1
(d), *2/2 vs *1/2 + *1/1 (e).
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the allele LAPTM4B*2 is associated with higher level of
LAPTM4B expression.
With the detections mentioned above, we hypothe-
sized that the effect of the genetic polymorphism in
LAPTM4B on cancer susceptibility may result from the
change in N-terminal region or from the change in ex-
pression level with different genotypes.
While the results of the studies concerning the rela-
tionship between LAPTM4B polymorphism and cancer
risk are inconsistent, we conducted this meta-analysis to
determine the strength of the association with a rela-
tively large sample size containing 4556 cases and 4584
controls. In our meta-analysis, the association between
LATPM4B polymorphism and cancer susceptibility
and the association between LAPTM4B expression
levels and cancer prognosis were observed in multiple
cancers. All above support our hypotheses of the asso-
ciation between LAPTM4B polymorphism and cancer
susceptibility.
This analysis has some limitations. One of the limita-
tions lies in the study population. All the populations
are Chinese. This may because that the gene is newly
discovered and the polymorphisms were initially de-
tected in Chinese Han population. And that our ana-
lysis indicated a strong relationship between this
polymorphism and cancer risk, this meta-analysis may
be a reference for further researches in other countries.
Second, the lack of raw data, including the information
of histology, family history and smoking status, limited
the assessment of interaction between gene-gene and
gene-environment.
Asides the limitations mentioned above, this study
presents some advantages. No publication bias and het-
erogeneity among studies were observed in this analysis,suggesting a stable and reliable result. Additionally, the
estimation of pooled ORs and 95%CIs was based on a
relatively large scale of cases and controls. In this view,
the results indicated a powerful association between the
genetic polymorphisms and cancer risk and may provide
a strong evidence for further researches.Conclusions
In summary, LAPTAM4B polymorphisms are associ-
ated with multiple cancer susceptibility and allele*2 is
a risk factor for various tumors. More studies on the
association of LAPTM4B polymorphisms and cancer
risk in other countries are warranted to confirm the
association.Methods
Identification and eligibility of relevant study
All of the studies were identified through five online
electronic databases including PubMed, web of science,
google scholar, CNKI and WanFang database, using the
search strategies “keywords or subjects or title or ab-
stract = (LAPTM4B AND polymorphism AND (cancer
OR carcinoma OR tumor OR sarcoma))”. Citation in-
dexes were performed and the reference list was
searched to identify potential relevant studies. The last
search update was Jun 29, 2014.
Studies involved in the meta-analysis should meet the
following inclusion criteria: (i) a case–control study; (ii)
frequency of genotype or allele is available; (iii) P value
of Hardy-Weinberg equilibrium for the distribution of
genotypes in control group should be no less than 0.05.
Articles will be excluded for: (1) no available data to cal-
culate OR or no original data to estimate the P value of
Hardy-Weinberg equilibrium; (2) duplicate publication;
Xia et al. SpringerPlus  (2015) 4:179 Page 7 of 8(3) meeting records or articles written neither in English
nor in Chinese.
Data extraction
Two authors worked independently to extract information
carefully. Any disagreement would be discussed until a
consensus was reached between two authors. Otherwise,
another author would check up the controversial informa-
tion and a final conclusion would be drawn from the vote
results. The information collected from each study con-
tained: the surname of first author, the publication year,
country of origin, ethnic group, type of tumor, frequency
of genotypes and alleles in cases and controls.
Statistic analysis
The strength of the association of LAPTM4B polymorph-
ism and cancer risk is measured by odd ratios (ORs) with
95% confidence intervals (CIs). The statistical significance
of the pooled ORs is determined by Z-test. We estimated
the cancer risk related to allele*2, compared to allele*1. For
genotypes, we estimated the OR associated with genotype
*1/2, *2/2 and allele*2 containing genotypes (*1/2 + *2/2),
compared with *1/1 homozygote, respectively. Stratified
analysis was performed according to the type of tumor.
Hardy-Weinberg equilibrium (HWE) was tested by
chi-square goodness of fit and a P value no less than
0.05 indicates that the study complies with Hardy-
Weinberg Law. The degree of heterogeneity among
studies was investigated by Q-statistic. A P value >0.05
indicated a lack of heterogeneity among studies and we
chose the fixed effect model (the Mantel-Haenszel
method). Otherwise, we selected a random effect model
(DerSimonian–Laird method). A funnel plot was used to
decide the presence of publication bias, in which the
standard error of log (OR) of each study was plotted
against its log (OR) and an asymmetric plot suggested
the existence of publication bias. Egger’s test was then
performed to verify the presence and determine the de-
gree of asymmetry. P < 0.05 was considered to indicate
the statistically significant publication bias. A sensitivity
analysis was carried out to identify the potential outliers.
P values were all based on two-way tests. The meta-
analysis was performed in STATA version 11.0.
Additional files
Additional file 1: Table S1. The pooled adjusted OR and 95%CI for the
estimation of association between LAPTM4B polymorphism and cancer
susceptibility.
Additional file 2: Table S3. The pooled HR and 95%CI for the
estimation of association between LAPTM4B expression and cancer
prognosis.
Additional file 3: Table S2. The eligible articles included in this
meta-analysis for the estimation of association between LAPTM4B
expression and cancer susceptibility.Additional file 4: Table S4. The stratified analysis for the estimation of
association between LAPTM4B expression and prognosis in different type
of cancer.
Abbreviations
LAPTM4B: Lysosome-associated protein transmembrane 4 beta; OR: Odds
ratio; CI: confidence interval; LMP: Lysosomal-membrane permeabilization;
SH2: src-homology 2; SH3: src-homology 3; PI3K: Phosphoinositide 3-kinase;
PKC: Protein kinase C.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XLZ designed and drafted the article, XLZ, SL and RYW searched the Internet
to identify articles, YZH, LXL and SL extracted and record the data, WW and
LXL conducted the statistical analysis, YZH and GP revised the article critically
for important intellectual content, ZBS provided the fund and gave final
approval of the version to be published.
Acknowledgements
This study was supported by grant NO.81272293 and NO.81102194 from
National Natural Science Foundation of China. The authors are most grateful
to all the participants in this study.
Received: 28 November 2014 Accepted: 23 March 2015
References
Burman C, Ktistakis NT (2010) Autophagosome formation in mammalian cells.
Semin Immunopathol 32(4):397–413, doi:10.1007/s00281-010-0222-z
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science
296(5573):1655–1657, doi:10.1126/science.296.5573.1655
Cheng XJ, Xu W, Zhang QY, Zhou RL (2008) Relationship between LAPTM4B
gene polymorphism and susceptibility of colorectal and esophageal cancers.
Ann Oncol 19(3):527–532, doi:10.1093/annonc/mdm469
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C,
Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes
tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.
Cancer Cell 10(1):51–64, doi:10.1016/j.ccr.2006.06.001
Dell’Angelica EC, Mullins C, Caplan S, Bonifacino JS (2000) Lysosome-related
organelles. FASEB J 14(10):1265–1278, doi:10.1096/fj.14.10.1265
Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A (2009) Life and death partners:
apoptosis, autophagy and the cross-talk between them. Cell Death Differ
16(7):966–975, doi:10.1038/cdd.2009.33
Fan M, Liu Y, Zhou R, Zhang Q (2012) Association of LAPTM4B gene polymorphism
with breast cancer susceptibility. Cancer Epidemiol 36(4):364–368, doi:10.1016/
j.canep.2011.12.004
Folkman J (2003) Angiogenesis and apoptosis. Semin Cancer Biol 13(2):159–167,
doi:10.1016/s1044-579x(02)00133-5
He J, Shao G, Zhou R (2003) Effects of the novel gene, LAPTM4B, highly
expression in hepatocellular carcinoma on cell proliferation and
tumorigenesis of NIH3T3 cells. J Peking Univ Health Sci 35(4):348–352
Hogue DL, Nash C, Ling V, Hobman TC (2002) Lysosome-associated protein
transmembrane 4 alpha (LAPTM4 alpha) requires two tandemly arranged
tyrosine-based signals for sorting to lysosomes. Biochem J 365:721–730
Honing S, Sandoval IV, von Figura K (1998) A di-leucine-based motif in the cytoplasmic
tail of LIMP-II and tyrosinase mediates selective binding of AP-3. EMBO J
17(5):1304–1314, doi:10.1093/emboj/17.5.1304
Hunziker W, Geuze HJ (1996) Intracellular trafficking of lysosomal membrane
proteins. Bioessays 18(5):379–389, doi:10.1002/bies.950180508
Jin S, White E (2007) Role of autophagy in cancer - Management of metabolic
stress. Autophagy 3(1):28–31
Johansson A-C, Appelqvist H, Nilsson C, Kagedal K, Roberg K, Ollinger K (2010)
Regulation of apoptosis-associated lysosomal membrane permeabilization.
Apoptosis 15(5):527–540, doi:10.1007/s10495-009-0452-5
Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, Castanos-Velez E, Staub E,
Mennerich D (2005) The human LAPTM4b transcript is upregulated in various
types of solid tumours and seems to play a dual functional role during tumour
progression. Cancer Lett 224(1):93–103, doi:10.1016/j.canlet.2004.10.004
Xia et al. SpringerPlus  (2015) 4:179 Page 8 of 8Kenific CM, Thorburn A, Debnath J (2010) Autophagy and metastasis:
another double-edged sword. Curr Opin Cell Biol 22(2):241–245,
doi:10.1016/j.ceb.2009.10.008
Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms
associated with altered intracellular distribution of anticancer agents.
Pharmacol Ther 85(3):217–229, doi:10.1016/s0163-7258(99)00073-x
Li C, Zhou Q, Wang Y, Chen X, Yang X, Zhu D (2006) Relationship between
LAPTM4B gene polymorphism and susceptibility of lung cancer. Chin J Lung
Cancer 9(2):109–112
Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao
GZ, Zhou RL (2010a) LAPTM4B: a novel cancer-associated gene motivates
multidrug resistance through efflux and activating PI3K/AKT signaling.
Oncogene 29(43):5785–5795, doi:10.1038/onc.2010.303
Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T, Yang Q (2012) LAPTM4B allele *2 is
associated with breast cancer susceptibility and prognosis. PLoS One
7(9):e44916, doi:10.1371/journal.pone.0044916
Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, Richardson AL
(2011) Lysosomal Transmembrane Protein LAPTM4B Promotes
Autophagy and Tolerance to Metabolic Stress in Cancer Cells. Cancer Res
71(24):7481–7489, doi:10.1158/0008-5472.can-11-0940
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z,
Iglehart JD, Richardson AL, Wang ZC (2010b) Amplification of LAPTM4B
and YWHAZ contributes to chemotherapy resistance and recurrence of
breast cancer. Nat Med 16(2):214–218, doi:10.1038/nm.2090
Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B
(1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1.
Nature 402(6762):672–676
Liu X-R, Zhou R-L, Zhang Q-Y, Zhang Y, Jin Y-Y, Lin M, Rui J-A, Ye D-X (2004) Structure
analysis and expressions of a novel tetratransmembrane protein, lysosome-
associated protein transmembrane 4 B associated with hepatocellular carcinoma.
World J Gastroenterol 10(11):1555–1559
Liu X, Xiong F, Wei X, Yang H, Zhou R (2009) LAPTM4B-35, a novel tetratransmembrane
protein and its PPRP motif play critical roles in proliferation and metastatic
potential of hepatocellular carcinoma cells. Cancer Sci 100(12):2335–2340,
doi:10.1111/j.1349-7006.2009.01346.x
Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, Zhang S, Lin M, Rui J, Ye D
(2003) Identification and characterization of LAPTM4B encoded by a
human hepatocellular carcinoma-associated novel gene. Beijing Da Xue
Xue Bao 35(4):340–347
Liu Y, Zhang QY, Qian N, Zhou RL (2007) Relationship between LAPTM4B gene
polymorphism and susceptibility of gastric cancer. Ann Oncol 18(2):311–316,
doi:10.1093/annonc/mdl394
Deng LJ, Zhang Q, Liu B, Zhou R (2005) Relationship between LAPTM4B gene
polymorphism and susceptibility of lung cancer. J Peking Univ Health Sci
37(3):302–305
Maeda K, Horikoshi T, Nakashima E, Miyamoto Y, Mabuchi A, Ikegawa S (2005)
MATN and LAPTM are parts of larger transcription units produced by
intergenic splicing: intergenic splicing may be a common phenomenon.
DNA Res 12(5):365–372, doi:10.1093/dnares/dsi017
Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto L, Garbisa S, Mignatti P (1997)
control of type iv collagenase activity by components of the urokinase-
plasmin system a regulatory mechanism with cell bound reactants. EMBO J
16(9):2319–2332
Medema RH, Kops G, Bos JL, Burgering BMT (2000) AFX-like Forkhead transcription
factors mediate cell-cycle regulation by Ras and PKB through p27(kip1). Nature
404(6779):782–787
Meng F, Li H, Zhou R, Luo C, Hu Y, Lou G (2013) LAPTM4B gene polymorphism
and endometrial carcinoma risk and prognosis. Biomarkers 18(2):136–143,
doi:10.3109/1354750X.2012.752526
Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R, Lou G (2011) Correlation of
LAPTM4B polymorphisms with cervical carcinoma. Cancer 117(12):2652–2658,
doi:10.1002/cncr.25833
Milde-Langosch K (2005) The Fos family of transcription factors and their role in
tumourigenesis. Eur J Cancer 41(16):2449–2461, doi:10.1016/j.ejca.2005.08.008
Qi R (2010) LAPTM4B gene polymorphism and liver cancer susceptibility. Chinese
PLA General Hospital & Postgraduate Medical School
Qu XP, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL,
Mizushima N, Ohsumi Y, Cattoretti G, Levine B (2003) Promotion of
tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.
J Clin Investig 112(12):1809–1820, doi:10.1172/jci200320039Scarlatti F, Granata R, Meijer AJ, Codogno P (2009) Does autophagy have a
license to kill mammalian cells? Cell Death Differ 16(1):12–20,
doi:10.1038/cdd.2008.101
Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X, Ye DX (2003)
Molecular cloning and characterization of LAPTM4B, a novel gene
upregulated in hepatocellular carcinoma. Oncogene 22(32):5060–5069,
doi:10.1038/sj.onc.1206832
Sun G, Li Z, Hao W, Niu J, Yin J, Yan Y (2008) Relationship between
lysosomeassociated protein transmembrane4βpolymorphism and
Susceptmmty to liver cancer. World Chin J Digestology 16(8):908–911
Sun L, Zhang Q, Liu Y, Qian N (2007) Relationship between Human Novel Gene
LAPTM4B Polymorphism and Susceptibility or Lymphoma. Cancer Res Prev
Treat 34(4):345–348
Tang H, Tian H, Yue W, Li L, Li S, Gao C, Si L, Qi L, Lu M, Hu W (2014) LAPTM4B
polymorphism is associated with nonsmall cell lung cancer susceptibility and
prognosis. Oncol Rep 31(5):2454–2460, doi:10.3892/or.2014.3116
Vergarajauregui S, Martina JA, Puertollano R (2010) LAPTMs regulate lysosomal
function and interact with mucolipin 1: new clues for understanding
mucolipidosis type IV. J Cell Sci 124:459–468, doi:10.1242/jcs
Wang B, Xu J, Zhou R, Zhang Q (2013) Association of LAPTM4B gene
polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese
population. Med Oncol 30(1):470, doi:10.1007/s12032-013-0470-6
Wang S, Zhang Q (2010) Association of lysosome associated protein
transmembrane 4 beta gene polymorphism with the risk of pancreatic
cancer. Chin J Cancer Res 22(4):291–295
Wang S, Zhang QY, Zhou RL (2012) Relationship between LAPTM4B gene
polymorphism and susceptibility of primary liver cancer. Ann Oncol
23(7):1864–1869, doi:10.1093/annonc/mdr538
White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in
cancer. Clin Cancer Res 15(17):5308–5316, doi:10.1158/1078-0432.CCR-07-5023
Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, Li X, Yang M, Lou G (2012) LAPTM4B
polymorphisms is associated with ovarian cancer susceptibility and its
prognosis. Jpn J Clin Oncol 42(5):413–419, doi:10.1093/jjco/hys026
Yan C, Boyd DD (2007) Regulation of Matrix metalloproteinase gene expression.
J Cell Physiol 211:19–26, doi:10.1002/jcp.2094810.1002/JCP
Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R (2010a) Overexpression of
LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma
in vitro and in vivo. Cancer Lett 294(2):236–244, doi:10.1016/
j.canlet.2010.02.006
Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL (2010b) LAPTM4B-35 overexpression
is a risk factor for tumor recurrence and poor prognosis in hepatocellular
carcinoma. J Cancer Res Clin Oncol 136(2):275–281, doi:10.1007/s00432-009-0659-4
Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA (2012) Correlation of LAPTM4B
polymorphisms with gallbladder carcinoma susceptibility in Chinese patients.
Med Oncol 29(4):2809–2813, doi:10.1007/s12032-012-0173-4
Yue ZY, Jin SK, Yang CW, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene
essential for early embryonic development, is a haploinsufficient tumor
suppressor. Proc Natl Acad Sci U S A 100(25):15077–15082, doi:10.1073/
pnas.2436255100
Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt MA, Li X (2012) Correlation of
LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients.
Med Oncol 29(4):2744–2749, doi:10.1007/s12032-011-0139-y
Zhou L, He X-D, Cui Q-C, Zhou W-X, Qu Q, Zhou R-L, Rui J-A, Yu J-C (2008)
Expression of LAPTM4B-35: A novel marker of progression, invasiveness
and poor prognosis of extrahepatic cholanglocarcinoma. Cancer Lett
264(2):209–217, doi:10.1016/j.canlet.2008.01.025
Zhou L, He XD, Yu JC, Zhou R, Xiong F, Qu Q, Rui JA (2010a) Expression of
LAPTM4B in gallbladder carcinoma cells_ the role in invasive potential.
Hepatogastroenterology 57:207–211
Zhou L, He XD, Yu JC, Zhou RL, Yang H, Qu Q, Rui JA (2010b) Overexpression of
LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg
199(4):515–521, doi:10.1016/j.amjsurg.2009.03.031
